$10.91 Million in Sales Expected for Minerva Surgical, Inc. (NASDAQ:UTRS) This Quarter

Analysts expect Minerva Surgical, Inc. (NASDAQ:UTRSGet Rating) to announce $10.91 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Minerva Surgical’s earnings, with estimates ranging from $10.22 million to $12.25 million. The firm is scheduled to issue its next quarterly earnings results after the market closes on Monday, January 1st.

According to Zacks, analysts expect that Minerva Surgical will report full-year sales of $61.21 million for the current financial year, with estimates ranging from $60.18 million to $61.86 million. For the next fiscal year, analysts forecast that the business will report sales of $81.21 million, with estimates ranging from $80.52 million to $81.62 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research firms that follow Minerva Surgical.

Several analysts recently issued reports on UTRS shares. Zacks Investment Research cut shares of Minerva Surgical from a “buy” rating to a “hold” rating in a report on Saturday, March 12th. Piper Sandler reduced their price objective on shares of Minerva Surgical from $17.00 to $12.00 and set an “overweight” rating for the company in a research note on Wednesday, March 9th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Minerva Surgical currently has an average rating of “Buy” and a consensus price target of $11.70.

Hedge funds have recently made changes to their positions in the stock. Novo Holdings A S bought a new position in shares of Minerva Surgical during the 4th quarter valued at about $10,574,000. Perceptive Advisors LLC bought a new position in Minerva Surgical during the 4th quarter worth $451,000. Ghisallo Capital Management LLC bought a new position in Minerva Surgical during the 4th quarter worth $386,000. Millennium Management LLC bought a new position in shares of Minerva Surgical in the 4th quarter valued at $134,000. Finally, BlackRock Inc. bought a new position in shares of Minerva Surgical in the 4th quarter valued at $88,000. Hedge funds and other institutional investors own 42.40% of the company’s stock.

Shares of UTRS stock opened at $2.42 on Friday. The firm’s 50 day simple moving average is $4.56. Minerva Surgical has a fifty-two week low of $2.24 and a fifty-two week high of $10.37. The company has a debt-to-equity ratio of 0.89, a quick ratio of 2.60 and a current ratio of 3.29.

Minerva Surgical Company Profile (Get Rating)

Minerva Surgical, Inc, a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company offers Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps.

Read More

Get a free copy of the Zacks research report on Minerva Surgical (UTRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Minerva Surgical (NASDAQ:UTRS)

Receive News & Ratings for Minerva Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Surgical and related companies with MarketBeat.com's FREE daily email newsletter.